Moreover, PRKDC can be a drug target for immune checkpoint inhibitors, while the inhibition of DNA-PK can also enhance the chemosensitivity and radiosensitivity of NSCLC. The gene discussed is PRKDC; the disease is non-small cell lung carcinoma.